Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02788474
Registration number
NCT02788474
Ethics application status
Date submitted
27/05/2016
Date registered
2/06/2016
Date last updated
21/12/2023
Titles & IDs
Public title
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Query!
Scientific title
A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment.
Query!
Secondary ID [1]
0
0
2015-003148-38
Query!
Secondary ID [2]
0
0
1199.227
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Connective tissue diseases
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - nintedanib
Treatment: Drugs - placebo
Placebo Comparator: placebo -
Experimental: nintedanib -
Treatment: Drugs: nintedanib
Treatment: Drugs: placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.
Query!
Assessment method [1]
0
0
The rate of change (slope) in blood C-reactive protein degraded by matrix metalloproteinase-1/8 (CRPM) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (CRPM log 10 transformed) with fixed effects for gender, age, height and random effect of patient specific intercept and time.
Query!
Timepoint [1]
0
0
baseline and 12 weeks
Query!
Secondary outcome [1]
0
0
Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52
Query!
Assessment method [1]
0
0
For this endpoint, disease progression was defined by absolute FVC (percentage of predicted) decline =10% or death up to Week 52 based on in-clinic supervised spirometry.
This is a key secondary endpoint of the trial. This outcome measure is "percentage of patients with disease progression" and CRPM is included in the various models as a factor/covariate, and that this outcome measure, the percentage of progressors are displayed under "Measured values"
Query!
Timepoint [1]
0
0
52 weeks
Query!
Secondary outcome [2]
0
0
The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12
Query!
Assessment method [2]
0
0
The rate of change in blood Collagen 1 degraded by matrix metalloproteinase-2/9/13 (C1M) from baseline to week 12 is presented.
The mean presented is the adjusted rate based on a random coefficient regression (C1M (negative reciprocal root transformation)) with fixed effects for gender, age, height and random effect of patient specific intercept and time.
Query!
Timepoint [2]
0
0
baseline and 12 weeks
Query!
Secondary outcome [3]
0
0
The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12
Query!
Assessment method [3]
0
0
The rate of change in blood Collagen 3 degraded by matrix metalloproteinase-9 (C3M) from baseline to week 12 is presented.
The mean presented is the adjusted rate based on a random coefficient regression (C3M- log 10 transformation) with fixed effects for gender, age, height and random effect of patient specific intercept and time.
Query!
Timepoint [3]
0
0
baseline and 12 weeks
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
- Written informed consent consistent with International Conference on Harmonisation
Good Clinical Practice and local laws, signed prior to participation in the trial
including any study related procedures being performed;
- Male or female patients aged >=40 years at Visit 1;
- A clinical diagnosis of Idiopathic pulmonary fibrosis (IPF) within the last 3 years
from visit 0, based upon the American Thoracic Society/ European Respiratory Society
/Japanese Respiratory Society/ Latin American Thoracic Association 2011 guideline;
- Chest high resolution computed tomography (HRCT) scan performed within 18 months of
Visit 0;
- Combination of HRCT pattern, and surgical lung biopsy pattern (the latter if
available) as assessed by central review are consistent with the diagnosis of
Idiopathic pulmonary fibrosis;
- Forced vital capacity (FVC) >=80% of predicted normal at Visit 1.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Alanine transaminase, Aspartate aminotransferase > 1.5 fold upper limit of normal
(ULN) at Visit 1;
- Total bilirubin > 1.5 fold ULN at Visit 1;
- Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic
impairment);
- Relevant airways obstruction, i.e. pre-bronchodilator Forced expiratory volume in 1
second / Forced vital capacity < 0.70;
- History of myocardial infarction within 6 months of visit 1 or unstable angina within
1 month of Visit 1;
- Bleeding Risk:
- Known genetic predisposition to bleeding;
- Patients who require fibrinolysis, full-dose therapeutic anticoagulation or high
dose antiplatelet therapy;
- History of haemorrhagic central nervous system (CNS) event within 12 months prior
to Visit 1;
- History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers
and/or major injury or surgery within 3 months prior to Visit 1;
- International normalised ratio (INR) > 2 at Visit 1;
- Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of ULN at
Visit 1;
- Planned major surgery during the trial participation, including lung transplantation,
major abdominal or major intestinal surgery;
- History of thrombotic event (including stroke and transient ischemic attack) within 12
months of Visit 1;
- Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault formula at Visit 1;
- Treatment with nintedanib, pirfenidone, azathioprine, cyclophosphamide, cyclosporine,
any other investigational drug, n-acetylcysteine, prednisone/prednisolone >15 mg daily
or >30 mg every 2 days OR use of other systemic corticosteroids as well as any
investigational drugs within 4 weeks of Visit 2;
- Known hypersensitivity to nintedanib, peanut, soya or to any other components of the
study medication;
- Prior discontinuation of nintedanib treatment due to intolerability/ adverse events
considered drug related;
- A disease or condition which in the opinion of the investigator may interfere with
testing procedures or put the patient at risk when participating in this trial;
- Alcohol or drug abuse which in the opinion of the treating physician would interfere
with the treatment and would affect patient's ability to participate in this trial;
- Patients not able to understand and follow any study procedures such as but not
limited to home spirometry, including completion of self-administered questionnaires
without help;
- Women who are pregnant, nursing, who plan to become pregnant while in the trial or
female patients with positive pregnancy (ß-HCG) test at Visit 1 and/or Visit 2;
- Women of childbearing potential4 not willing or able to use highly effective methods
of birth control per International Conference on Harmonisation (ICH) M3 (R2) that
result in a low failure rate of less than 1% per year when used consistently and
correctly.
- Patients with acute IPF exacerbation or any respiratory tract infection in the four
weeks prior to Visit 1 or during the screening period;
- Patients who are or have been participating in another trial with investigational
drug/s within one month prior to Visit 1 and patients who have previously been
enrolled in this trial;
- Further exclusion criteria apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/06/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
8/06/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
347
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown, Sydney
Query!
Recruitment hospital [2]
0
0
Concord General Repatriation Hospital -Ambulatory Care Unit - Concord
Query!
Recruitment hospital [3]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [4]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown, Sydney
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Minnesota
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Missouri
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Ohio
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Virginia
Query!
Country [8]
0
0
Belgium
Query!
State/province [8]
0
0
Bruxelles
Query!
Country [9]
0
0
Belgium
Query!
State/province [9]
0
0
Edegem
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Leuven
Query!
Country [11]
0
0
Belgium
Query!
State/province [11]
0
0
Liège
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Yvoir
Query!
Country [13]
0
0
Czechia
Query!
State/province [13]
0
0
Olomouc
Query!
Country [14]
0
0
Czechia
Query!
State/province [14]
0
0
Plzen
Query!
Country [15]
0
0
Czechia
Query!
State/province [15]
0
0
Praha 4
Query!
Country [16]
0
0
Czechia
Query!
State/province [16]
0
0
Praha
Query!
Country [17]
0
0
Czechia
Query!
State/province [17]
0
0
Usti nad Labem
Query!
Country [18]
0
0
Finland
Query!
State/province [18]
0
0
Helsinki
Query!
Country [19]
0
0
Finland
Query!
State/province [19]
0
0
Kuopio
Query!
Country [20]
0
0
Finland
Query!
State/province [20]
0
0
Oulu
Query!
Country [21]
0
0
Finland
Query!
State/province [21]
0
0
Tampere
Query!
Country [22]
0
0
Finland
Query!
State/province [22]
0
0
Turku
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Brest
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Bron
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Paris
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Reims Cedex
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Rennes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Strasbourg
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Tours
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Bamberg
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Berlin
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Gießen
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Greifswald
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Grosshansdorf
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Hannover
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Heidelberg
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Immenhausen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
München
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Münster
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Budapest
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Deszk
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Farkasgyepu
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Miskolc
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Aichi, Seto
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Fukuoka, Kurume
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Ibaraki, Naka-gun
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Kanagawa, Yokohama
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Osaka, Osakasayama
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Osaka, Sakai
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Tokushima, Tokushima
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Tokyo, Bunkyo-ku
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Tokyo, Ota-ku
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Tokyo, Shinjuku-ku
Query!
Country [54]
0
0
Korea, Republic of
Query!
State/province [54]
0
0
Seongnam
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Seoul
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Bydgoszcz
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Katowice
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Krakow
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Lodz
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Torun
Query!
Country [61]
0
0
Spain
Query!
State/province [61]
0
0
Barcelona
Query!
Country [62]
0
0
Spain
Query!
State/province [62]
0
0
Galdakao
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
L'Hospitalet Llobregat (bcn)
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Majadahonda (Madrid)
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Pozuelo de Alarcón
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Sabadell
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Sevilla
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Valencia
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Bristol
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Cambridge
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Exeter
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
London
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
Manchester
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Identifying biomarkers to predict the clinical course and benefits of therapy early in the
course of the disease remains one of the most urgent and relevant challenges to improve
overall patient management, to prevent treatment delay or overtreatment. This study is
conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of
extracellular matrix turnover which have been shown recently to correlate with disease
progression. This study further aims to confirm the association of biomarker course during
the first three months of treatment and disease progression.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02788474
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02788474
Download to PDF